LAUSR

Surgical treatment of locally advanced lung cancer is a major challenge in thoracic surgery. Neoadjuvant therapy has proven to be useful for tumor regression, while increasing surgical resection rates (1). Neoadjuvant chemotherapy combined with immunotherapy is a new treatment model for locally advanced lung cancer, which can not only improve surgical resection rates, but also improves patient prognosis (2,3). Whether difficulties in surgical resection and postoperative complications still increase is worth exploring. We report a patient with locally advanced left lower lobe lung squamous carcinoma (stage IIIA, T2N2M0) who accepted 2 cycles of paclitaxel/ carboplatin/pembrolizumab neoadjuvant chemotherapy combined with immunotherapy. We then performed singledirection video-assisted thoracoscopic left lower lobectomy and lymph node dissection, and the surgical procedure is described below. We present the following article in accordance with the CARE reporting checklist (available at http://dx.doi.org/10.21037/jtd-21-529).